Showing 8701-8710 of 9965 results for "".
- Allergies to Pre-Moistened Wipes on the Risehttps://practicaldermatology.com/news/20140303-allergies_to_pre-moistened_wipes_on_the_rise/2459326/A preservative in pre-moistened hand wipes may be linked to a rise of allergic reactions, according to dermatologist Matthew Zirwas, MD at the Ohio State University Wexner Center. He says manufacturers are increasing use of the preservative as they reduce their dependence on formaldehyde and para
- Ellman to Launch PelleFirm at Annual Meeting of the AADhttps://practicaldermatology.com/news/20140227-ellman_to_launch_pellefirm_at_annual_meeting_of_the_aad/2459327/Ellman International, Inc., received FDA clearance to market its new PelleFirm RF Body Treatment System. The PelleFirm System is CE Marked for body skin tightening and cellulite reduction. In addition, it also has received FDA 510(K) clearance for tissue heating and the temporar
- Foamix, Ltd. Will Present Phase II Results for Topical Minocycline at Upcoming Conferencehttps://practicaldermatology.com/news/20140227-foamix_ltd_will_present_phase_2_results_for_topical_minocycline_at_upcoming_conference/2459328/Foamix will present the successful results from its Phase II clinical trials with topical minocycline for acne and impetigo at the 34th Annual Cowen & Company Health Care Conference. The pharmaceutical company, which focuses on the development of patented topical foams for de
- Mirvaso Approved by the European Commissionhttps://practicaldermatology.com/news/20140226-mirvaso_approved_by_the_european_commission/2459330/The European Commission has granted marketing authorization in Europe for Galderma's Mirvaso (brimonidine) 3 mg/g gel. Mirvaso, an alpha-2 adrenergic receptor agonist that acts rapidly and can last for up to 12 hours, is indicated for the symptomatic tr
- Promius Pharma, LLC Introduces Dr. Reddy's Authorized Generic Producthttps://practicaldermatology.com/news/20140225-promius_pharma_llc_introduces_dr_reddys__authorized_generic_product/2459331/Promius Pharma, LLC, launched its first Authorized Generic (AG) of Cloderm® Cream through its parent company Dr. Reddy's Laboratories on February 14. The AG is identical in formulation to Cloderm® Cream and will provide all the similar benefits, while increasing access and reducing pharmacy call
- XOMA Gains Orphan Drug Designation to Treat Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20140225-xoma_gains_orphan_drug_designation_to_treat_pyoderma_gangrenosum/2459332/The FDA approved XOMA Corporation's IL-1 beta antibody gevokizumab for the treatment of pyoderma gangrenosum (PG) under an orphan drug designation. PG is a rare disorder of expanding, painful skin ulcers, which affects one in about 100,000 people. "Selecting pyoderma gangrenosum as our n
- Registration Open for Dermatology Nurses' Associaion's 32nd Annual Conventionhttps://practicaldermatology.com/news/20140221-registration_open_for_dermatology_nurses_associaions_32nd_annual_convention/2459335/The Dermatology Nurses' Association's 32nd Annual Convention will be held Thursday, May 1, 2014 through Sunday, May 4, 2014 at the Walt Disney World Swan and Dolphin Hotel, in Orlando, FL. Online registration is
- Topix Pharmaceuticals Introduces Replenix Restorative Nighttime Bio-Therapyhttps://practicaldermatology.com/news/20140213-topix_pharmaceuticals_introduces_replenix_restorative_nighttime_bio-therapy/2459344/Topix Pharmaceuticals, Inc., launched its Replenix Restorative Nighttime Bio-Therapy cream, a moisture-boosting, rich night cream formulated to attract, hold, and distribute moisture through a system of ceramides, humectants, and em
- Revance Therapeutics Announces Pricing of Initial Public Offeringhttps://practicaldermatology.com/news/20140207-revance_therapeutics_announces_pricing_of_initial_public_offering/2459346/Revance Therapeutics, Inc., a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $16.00 per share, befo
- Valeant Pharmaceuticals Announces FDA Approval of Retin-A Micro Microsphere 0.08%https://practicaldermatology.com/news/20140131-valeant_pharmaceuticals_announces_fda_approval_of_retin-a_micro_microsphere_008/2459353/The FDA approved Valeant Pharmaceuticals' Supplemental New Drug Application (sNDA) for Retin-A Micro (tretinoin) Gel microsphere 0.08% for the topical treatment of acne vulgaris. "We are very pleased that the FDA ha